Actinogen Medical Ltd has released a press release.
R&D Tax Incentive rebate received of $4.58 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- September 2019 Quarterly Update
- Cognitive improvement demonstrated with Xanamem
- June 2019 Quarterly Update
- Xanamen Clinical Development & Investor Update
- XanaHES Trial to Continue
Later from Actinogen Medical
- ACW 2019 AGM Chairman's Address
- December 2019 Quarterly Update
- Market Update COVID-19
- Appendix 4E & Annual Report
- ACW announces two clinical trials & launches capital raising
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical